Cargando…

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and panitumumab is the main targeted treatment to combine with standard chemotherapy for metastatic colorectal cancer. Many clinical studies have shown the benefit of the addition of these agents for patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bronte, Giuseppe, Silvestris, Nicola, Castiglia, Marta, Galvano, Antonio, Passiglia, Francesco, Sortino, Giovanni, Cicero, Giuseppe, Rolfo, Christian, Peeters, Marc, Bazan, Viviana, Fanale, Daniele, Giordano, Antonio, Russo, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694794/ https://www.ncbi.nlm.nih.gov/pubmed/26318427

Ejemplares similares

Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines
por: Fanale, Daniele, et al.
Publicado: (2013)

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
por: Passiglia, Francesco, et al.
Publicado: (2016)

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
por: Passiglia, Francesco, et al.
Publicado: (2018)

Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis
por: Galvano, Antonio, et al.
Publicado: (2019)

Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
por: Passiglia, Francesco, et al.
Publicado: (2018)

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway
por: Massihnia, Daniela, et al.
Publicado: (2016)

Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups
por: Passiglia, Francesco, et al.
Publicado: (2021)

Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus
por: Cabibi, Daniela, et al.
Publicado: (2016)

The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status
por: Bronte, Giuseppe, et al.
Publicado: (2016)

Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1
por: Badalamenti, Giuseppe, et al.
Publicado: (2019)

Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients
por: Passiglia, Francesco, et al.
Publicado: (2019)

Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?
por: Fanale, Daniele, et al.
Publicado: (2015)

MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness?
por: Caruso, S, et al.
Publicado: (2012)

Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin
por: Rizzo, Sergio, et al.
Publicado: (2017)

Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
por: Fanale, Daniele, et al.
Publicado: (2016)

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
por: Incorvaia, Lorena, et al.
Publicado: (2019)

“Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors
por: Incorvaia, Lorena, et al.
Publicado: (2016)

How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis
por: Galvano, Antonio, et al.
Publicado: (2019)

Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252)
por: Galvano, Antonio, et al.
Publicado: (2020)

What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment
por: Bronte, Enrico, et al.
Publicado: (2015)

Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma
por: Incorvaia, Lorena, et al.
Publicado: (2016)

Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)—Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes
por: Incorvaia, Lorena, et al.
Publicado: (2020)

Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward
por: Papadimitriou, Konstantinos, et al.
Publicado: (2015)

Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway
por: La Paglia, Laura, et al.
Publicado: (2017)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
por: Gristina, Valerio, et al.
Publicado: (2020)

Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis
por: Galvano, Antonio, et al.
Publicado: (2020)

The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis
por: Galvano, Antonio, et al.
Publicado: (2022)

Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs)
por: Incorvaia, Lorena, et al.
Publicado: (2021)

Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay
por: Incorvaia, Lorena, et al.
Publicado: (2023)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Van Emburgh, Beth O., et al.
Publicado: (2016)

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses
por: Gristina, Valerio, et al.
Publicado: (2021)

The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
por: Galvano, A., et al.
Publicado: (2021)

Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon
por: Incorvaia, Lorena, et al.
Publicado: (2021)

Editorial: The Effect of the COVID-19 Pandemic on Cancer Patients and Healthcare
por: Silvestris, Nicola, et al.
Publicado: (2022)

Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score
por: Galvano, Antonio, et al.
Publicado: (2020)

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
por: Russo, Alessandro, et al.
Publicado: (2015)

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?
por: Incorvaia, Lorena, et al.
Publicado: (2019)

Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2
por: Fanale, Daniele, et al.
Publicado: (2020)

Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?
por: Fanale, Daniele, et al.
Publicado: (2021)

COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?
por: Brunetti, Oronzo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gsvk4kh32h0n7i5vfb1anp6d5n